Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Shortage Notification Mandate May Not Extend To Biologics

Executive Summary

The agency has the option to issue regulations requiring biologics manufacturers to notify FDA of emerging production problems, but so far it’s only “something that we’re thinking about.”

You may also be interested in...



Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping

Rep. Kurt Schrader’s bill could allow a first interchangeable product to block all strengths with its one-year exclusivity, rather than just the one developed.

Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping

Rep. Kurt Schrader’s bill could allow a first interchangeable product to block all strengths with its one-year exclusivity, rather than just the one developed.

Drug Shortage Prevention May Fall To Payers As FDA Rolls Out New Reg

Even as agency touts its progress and expands its powers, it acknowledges the limits of notification.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel